Discover and read the best of Twitter Threads about #Sarilumab

Most recents (7)

Anti IL-6 en pacientes críticamente enfermos con Covid-19 - Informe preliminar.

Investigadores de REMAP-CAP.

medrxiv.org/content/10.110…
El ensayo muestra que los pacientes que reciben tocilizumab y un segundo fármaco : sarilumab, pueden reducir el riesgo relativo de muerte en un 24% cuando se administran a los pacientes dentro de las 24 horas posteriores al ingreso en cuidados intensivos.
Los pacientes tienen un impacto significativo en la supervivencia.
nihr.ac.uk/news/arthritis…
Read 14 tweets
@remap_cap is proud to announce the findings of IL-6 blockade in critically ill patients with #COVID19.
medrxiv.org/cgi/content/sh… (1/10)
353 patients randomized to #tocilizumab, 48 to #sarilumab, and 402 to control.
Adjusted odds ratio for improvement on organ-support free days at day 21 was 1.64 (CrI 1.25 - 2.18) and 1.89 (1.24 - 3.48), respectively. (2/10)
Mortality was 28% with tocilizumab, 22.2% for sarilumab (combined 27.3%), and 35.8% for control, with benefit of IL-6 blockade on all secondary outcomes collected. (3/10)
Read 10 tweets
#NewsApp Actualizamos toda la evidencia que hasta ahora se conoce sobre los tratamientos contra el COVID-19 con el gran aporte de @EpistemonikosEs. Hoy también encontrarán novedades: la #Hidrocortisona [Hilo]

saludconlupa.com/comprueba/cien…
Ahora sabemos la #hidrocortisona, un corticoide al igual que dexametasona, funciona para el tratamiento de casos graves de COVID-19 (aquellos que requieren atención en unidades de cuidados intensivos). La OMS recopiló los resultados de todos los ensayos que lo confirman.
Las nuevas revisiones permiten conocer también que #tocilizumab, #sarilumab y #azitromicina bajaron su clasificación de evidencia y son ahora poco prometedores como terapia COVID-19.

👨‍🔬👩‍🔬🧪saludconlupa.com/terapias-covid…
Read 3 tweets
How we’ll we manage the first ten #COVID19 patients of 2021 (if any) hospitalized for #ARDS (compared to the first 10 patients we managed in February 2020). A multidisciplinary brain storming after managing approx 1000 such patients within the end of Apr 2020. A thread 1/ #FOAMed Image
2/
Not all our clinical impressions have already published evidence (but the majority was published), but our hospital #COVID19 mortality went close to zero in late April 2020 and we hope medical management accounts for at least part of these results.
3/
More, early ECMO. We put a dozen ECMO. We feel we should have put more of them and we should have done it earlier (eg after a couple of days of invasive mechanical ventilation with no improvement). @annamarascandro
@mgcalabroMD @md_monaco @MarinaPieri4
hsr.it/news/2020/magg…
Read 11 tweets
1/
I want to thank all my colleagues for the wonderful #COVID19 research they published during these months: >200 PubMed-indexed articles from @SanRaffaeleMI @SRAnesthesiaICU @MyUniSR @azangrillo
I’ll summarize few of them in this thread.
2/
In February, before the start of #COVID19 in Europe, we suggested the use of helmet to deliver #CPAP #NIV in emergency departments. This can be a key issue to prevent future spread of respiratory pandemics in emergency departments.
thelancet.com/journals/lance…
3/
As soon as #COVID19 spread in Lombardy we helped other centers to manage their worst patients: 39 patients from other centers were admitted in our ICUs. The H was reshaped to cope with the new situation. The manusc cited 38 times in the first 4 months.
Read 19 tweets
Starting a series on clinical Pearls I am gathering in #COVID19 patients based on experiences of many experts

Will add as we go along

Feel free to add your own observations/experiences

#covidclinicalpearls /1
Anosmia is likely the most specific #COVID19 related symptom
30% of patients have anosmia as their 1st symptom
#covidclinicalpearls /2
Around 90% of patients have fever.
50% maybe afebrile at the time of presentation
Fever tends to be very resistant to routine measures in hospitalized patients
There is no consensus that NSAIDs are to be avoided in #COVID2019 patients

#covidclinicalpearls /3
Read 66 tweets
There is no proven effective antiviral drug for the treatment of #SARSCoV2

Several compounds are suggested for Rx of #COVID19. Based on the available in vitro and clinical data, which one is your preferred Rx, if available? #MayoIDQ references follow...
1/
#Chloroquine
Anti-malaria

Several potential mechanisms: change in cell membrane pH, impairs viral fusion, interferes with glycosylation of viral proteins

#chloroquine and #redemsivir are active against SARS-COV2 in experimental models

doi.org/10.1038/s41422…
2/
#Hydroxychloroquine
- Analogue of chloroquine
- Anti inflammatory effect

Hydroxychloroquine was more potent than chloroquine against #SARS-CoV2 in vitro.

doi.org/10.1093/cid/ci…
Read 17 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!